D. Stewart

发表

The BATTLE trial: personalizing therapy for lung cancer.

Edward S. Kim, S. Lippman, F. Khuri, 2011, Cancer discovery.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

Ara A Vaporciyan, Stephen G Swisher, J Jack Lee, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A cancer trial scandal and its regulatory backlash

R. Kurzrock, H. Kantarjian, D. Stewart, 2014, Nature Biotechnology.

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Michael Peyton, John D. Minna, Lixia Diao, 2013, Clinical Cancer Research.

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

J. Carmichael, F. Shepherd, J. von Pawel, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

R. Kurzrock, F. Janku, D. Stewart, 2011, Nature Reviews Clinical Oncology.

Phase I study of intracarotid administration of carboplatin.

D. Stewart, H. Hugenholtz, J. Belanger, 1992, Neurosurgery.

A network approach to developing immuno-oncology combinations in Canada.

H. McArthur, S. Verma, G. Batist, 2019, Current oncology.

Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data

Pearl A. Campbell, Gareth A. Palidwor, T. Perkins, 2020, BMC medical genomics.

Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data

Pearl A. Campbell, Gareth A. Palidwor, T. Perkins, 2019, bioRxiv.

Multiple resistance modulators combined with carboplatin for resistant malignancies: A pilot study

D. Stewart, J. Yau, M. Cripps, 2004, Investigational New Drugs.

Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies

S. Dahrouge, E. Tomiak, D. Stewart, 1997, Cancer Chemotherapy and Pharmacology.

Risk of Intracranial Hemorrhage and Cerebrovascular Accidents in Non-small Cell Lung Cancer Brain Metastasis Patients

Lei Feng, Y. Oh, Sarah H. Taylor, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients

Y. Oh, Sarah H. Taylor, D. Stewart, 2007 .

Brain metastases with an unknown primary: a clinical perspective

L. Eapen, C. Danjoux, L. Gerig, 1988, Journal of Neuro-Oncology.

Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.

D. Coyle, S. Dahrouge, D. Stewart, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Costs o f T reating a nd P reventing N ausea a nd V omiting in P atients R eceiving C hemotherapy

D. Coyle, S. Dahrouge, D. Stewart, 1999 .

A prospective intervention to improve happiness and reduce burnout in oncologists

G. Nicholas, M. Brackstone, B. Hutton, 2018, Supportive Care in Cancer.

Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate.

L. Klotz, D. Stewart, I. Davis, 1988, Seminars in oncology.

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.

R. Govindan, P. Postmus, A. Ardizzoni, 2020, Future oncology.

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

R. Govindan, P. Postmus, A. Ardizzoni, 2021, Frontiers in Oncology.

Rechallenge Strategy in Cancer Therapy

D. Stewart, M. Ong, T. Asmis, 2020, Oncology.

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

I. Tsigelny, R. Kurzrock, J. Wheler, 2015, Oncotarget.

Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program.

I. Wistuba, J. Lee, R. Herbst, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity.

A. Nanji, J. Maroun, D. Stewart, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis

G. Raaphorst, D. Stewart, J. Yau, 2004, Investigational New Drugs.

Wnt Signaling Pathway Pharmacogenetics in Non-Small Cell Lung Cancer

M. Spitz, Xifeng Wu, Y. Ye, 2014, The Pharmacogenomics Journal.

Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

W. Hong, I. Wistuba, J. Lee, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of intracarotid administration of carboplatin.

D. Stewart, H. Hugenholtz, J. Belanger, 1992 .

Oral Etoposide and Carboplatin: Effective Therapy for Elderly Patients with Small Cell Lung Cancer

S. Dahrouge, G. Goss, E. Tomiak, 1995, American journal of clinical oncology.

Regional process redesign of lung cancer care: a learning health system pilot project.

C. Dennie, J. Pantarotto, D. Maziak, 2018, Current oncology.

Determinants of the Cancer Drug Funding Process in Canada

John J. Shin, P. Wheatley‐Price, D. Stewart, 2022, Current oncology.

Foreword--new directions for topotecan in lung cancer treatment.

D. Stewart, 2004, The oncologist.

Phase II study of lonidamine plus radiotherapy in the treatment of brain metastases

L. Eapen, D. Stewart, S. Verma, 2005, Journal of Neuro-Oncology.

Nausea and Vomiting: Recent Research and Clinical Advances

Alan D. Miller, A. D. Miller, J. Kucharczyk, 1991 .

Genetic Variations in the Regulator of G-Protein Signaling Genes Are Associated with Survival in Late-Stage Non-Small Cell Lung Cancer

J. Gu, Xifeng Wu, J. Roth, 2011, PloS one.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

R. Herbst, J. Heymach, F. D. De Braud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer.

L. Eapen, J. Crook, C. Danjoux, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deficient G2-M and S Checkpoints are Associated with Increased Lung Cancer Risk: A Case-Control Analysis

M. Spitz, Hushan Yang, Xifeng Wu, 2007, Cancer Epidemiology Biomarkers & Prevention.

CXCR4 chemokine receptor antagonists: perspectives in SCLC

J. Burger, D. Stewart, 2009, Expert opinion on investigational drugs.

Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non–Small Cell Lung Carcinoma Cells12

T. Perkins, H. Sekhon, J. Bar, 2016, Neoplasia.

Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.

Derick R. Peterson, I. Wistuba, S. Swisher, 2014, Lung cancer.

Tissue platinum concentration and tumor response in non-small-cell lung cancer.

I. Wistuba, J. Lee, S. Swisher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on the role of topotecan in the treatment of non-small cell lung cancer.

D. Stewart, 2004, The oncologist.

Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non–Small Cell Lung Cancer Patients

R. Kurzrock, D. Stewart, 2016, Clinical Cancer Research.

Potential of CXCR 4 antagonists for the treatment of metastatic lung cancer

A. Peled, J. Burger, O. Wald, 2008 .

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

L. Seymour, H. Hirte, W. Miller, 2005, Investigational New Drugs.

Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy

G. Ayers, F. Fossella, Wei Wei, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of egfr tki-induced dermatologic adverse events.

N. Leighl, K. Papp, B. Melosky, 2015, Current oncology.

Before we throw out progression-free survival as a valid end point...

D. Stewart, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics and the impact of surgery and chemotherapy on survival of patients with advanced and metastatic bronchioloalveolar carcinoma: a retrospective study.

S. Dahrouge, D. Maziak, F. Shamji, 2000, Clinical lung cancer.

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.

R. Herrmann, C. Heussel, F. Shepherd, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib maintenance in stage III non-small-cell lung cancer.

D. Stewart, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era.

H. Kantarjian, D. Steensma, N. Jain, 2016, Journal of oncology practice.

Two patients with non-regional metastases of adenocarcinoma of the lung 11 and 14 years following surgery

J. Maroun, D. Stewart, B. Nair, 1990 .

Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.

A. Tsao, R. Kurzrock, F. Janku, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ATM sequence variants associate with susceptibility to non‐small cell lung cancer

M. Spitz, Hushan Yang, Xifeng Wu, 2007, International journal of cancer.

Phase II study of lonidamine in metastatic prostatic carcinoma

D. Stewart, S. Aitken, N. Futter, 1991, Investigational New Drugs.

PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas

L. Eapen, S. Dent, D. Stewart, 1996, Journal of Neuro-Oncology.

Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features

Stephen G Swisher, B Nebiyou Bekele, Shyam Biswal, 2010, Clinical Cancer Research.

Novel Therapeutic Targets in Non-small Cell Lung Cancer

Razelle Kurzrock, R. Kurzrock, F. Janku, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer diagnosis transformation: Aligning the people, processes, and technology sides of the learning system.

C. Dennie, J. Pantarotto, D. Maziak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant

D. Stewart, Quincy Chau, 1999, Cancer Chemotherapy and Pharmacology.

Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas

S. Dahrouge, D. Stewart, H. Hugenholtz, 2005, Journal of Neuro-Oncology.

Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration

C. Dulberg, M. Redmond, D. Stewart, 2004, Cancer Chemotherapy and Pharmacology.

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

C. Dulberg, M. Redmond, D. Stewart, 1997, Cancer Chemotherapy and Pharmacology.

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).

K. Bélanger, L. Seymour, D. Macdonald, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.

D. Stewart, D. Redmond, J. Molepo, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human autopsy tissue concentrations of mitoxantrone.

R. M. Green, J. Maroun, D. Stewart, 1986, Cancer treatment reports.

Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study.

E. Eisenhauer, J. Pater, J. Maroun, 1984, Cancer treatment reports.

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

R. Herbst, D. Prager, I. Dimery, 2005 .

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

R. Herbst, J. Heymach, D. Prager, 2005 .

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

S. Gertler, G. Goss, E. Tomiak, 1996, Lung cancer.

Non-chemotherapeutic agents that potentiate chemotherapy efficacy.

D. Stewart, W. Evans, W. Evans, 1989, Cancer treatment reviews.

A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer.

D. Stewart, S. Aitken, S. Huan, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Intracarotid infusion of cis‐diamminedichloroplatinum in the treatment of recurrent malignant brain tumors

S. Handel, W. S. Fields, S. Wallace, 1984, Cancer.

DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

M. Spitz, Q. Wei, C. Amos, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.

W. Hong, I. Wistuba, R. Herbst, 2010 .

A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer.

C. Earle, S. Gertler, Y. Cormier, 1998, Lung cancer.

A Phase II Study of 5‐Fluorouracil Plus High‐Dose Folinic Acid in the Treatment of Recurrent Small Cell Lung Cancer

S. Dahrouge, D. Stewart, W. Evans, 1995, American journal of clinical oncology.

MR imaging of linitis plastica of the rectum.

D. Stewart, S. Susnerwala, M. Dobson, 2003, AJR. American journal of roentgenology.

A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.

S. Handel, S. Wallace, R. Benjamin, 1982, Cancer research.

Human tissue distribution of platinum after cis-diamminedichloroplatinum

R. Caprioli, R. Benjamin, L. Feun, 1982, Cancer Chemotherapy and Pharmacology.

Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.

R. Benjamin, C. Wiseman, M. Burgess, 1980, Cancer research.

Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.

S. Dahrouge, K. Pritchard, M. Trudeau, 1990, Seminars in oncology.

Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer

F. Shamji, D. Stewart, W. Evans, 1997, Cancer Chemotherapy and Pharmacology.

Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: a case report.

D. Stewart, L. Stolbach, N. Russell, 1983, Cancer treatment reports.

Human central nervous system pharmacology of pentamethylmelamine and its metabolites

R. Benjamin, F. Cabanillas, D. Stewart, 2004, Journal of Neuro-Oncology.

Second malignancies in hairy cell leukemia (leukemic reticuloendotheliosis)

M. Keating, D. Stewart, 1982, American journal of hematology.

The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis).

R. Benjamin, M. Keating, D. Stewart, 1979, Blood.

VP-16, ifosfamide and cisplatin (VIP) for extensive small cell lung cancer.

E. Warner, F. Shepherd, S. Dahrouge, 1994, European journal of cancer.

A phase III study of high-dose intensification without hematopoietic progenitor cells support for patients with high-risk primary breast carcinoma.

S. Gertler, E. Tomiak, D. Stewart, 2000, American journal of clinical oncology.

Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity

A. Nanji, D. Stewart, N. Mikhael, 2004, Cancer Chemotherapy and Pharmacology.

Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.

R. M. Green, M. Redmond, D. Stewart, 1995, British Journal of Cancer.

Human Central Nervous System Pharmacology of Antineoplastic Agents: Implications for the Treatment of Brain Tumors

D. Stewart, 1987 .

Compliance in early-phase cancer clinical trials research.

R. Kurzrock, D. Stewart, 2013, The oncologist.

A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.

R. Natale, D. Stewart, P. Stella, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors

D. Stewart, H. Hugenholtz, R. Bélanger, 2004, Journal of Neuro-Oncology.

Response of brain metastases from breast cancer to megestrol acetate: A case report

S. Dahrouge, D. Stewart, 2005, Journal of Neuro-Oncology.

Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer

Y. Oh, W. William, R. Zinner, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CXCR4 chemokine receptor antagonists: perspectives in SCLC.

J. Burger, D. Stewart, 2009, Expert opinion on investigational drugs.

A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas

R. Benjamin, N. Savaraj, L. Feun, 1983, Journal of Neuro-Oncology.

Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study

D. Stewart, J. Costanzi, M. al-Sarraf, 2004, Journal of Neuro-Oncology.

Cisplatin plus cytosine arabinoside in adults with malignant gliomas

J. Maroun, D. Stewart, H. Hugenholtz, 2004, Journal of Neuro-Oncology.

Combined intraarterial and systemic chemotherapy for intracerebral tumors.

D. Stewart, H. Hugenholtz, Z. Grahovac, 1987, Neurosurgery.

Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas

S. Dahrouge, O. Agboola, D. Stewart, 1997, Journal of Neuro-Oncology.

Phase II study of topotecan in patients with recurrent malignant glioma

E. Eisenhauer, D. Macdonald, C. Sawka, 1996 .

Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA)

R. Benjamin, M. Keating, N. Savaraj, 1984, Cancer Chemotherapy and Pharmacology.

Feasibility study of combining metronidazole with chemotherapy.

J. Maroun, D. Stewart, H. Hugenholtz, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer therapy, vomiting, and antiemetics.

D. Stewart, David J. Stewart, 1990, Canadian journal of physiology and pharmacology.

Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer.

L. Eapen, J. Collins, D. Stewart, 2004, The Journal of urology.

The role of chemotherapy in the treatment of gliomas in adults.

D. Stewart, David J. Stewart, 1989, Cancer treatment reviews.

Intraarterial Chemotherapy for Brain Tumors: A Summary of the Ottawa Experience

D. Stewart, 1987 .

Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer.

D. Stewart, J. Yau, S. Aitken, 1999, American journal of clinical oncology.

Concentrations of vinblastine in human intracerebral tumor and other tissues

R. Benjamin, D. Stewart, M. Leavens, 2004, Journal of Neuro-Oncology.

Concentration of vinblastine in human intracerebral tumor and other tissues.

R. Benjamin, D. Stewart, M. Leavens, 1983, Journal of neuro-oncology.

Pros and cons of intra-arterial chemotherapy.

D. Stewart, 1989, Oncology.

Platinum Concentrations in Human Autopsy Tumor Samples

A. Nanji, J. Maroun, D. Stewart, 1988, American journal of clinical oncology.

Central nervous system pharmacology of Baker's antifolate (NSC139105) in man

R. Benjamin, D. Stewart, M. Leavens, 1984, Journal of Neuro-Oncology.

Antiandrogen withdrawal syndrome with nilutamide.

D. Stewart, J. Yau, R. Gerridzen, 1997, Urology.

Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations.

A. Nanji, D. Stewart, N. Mikhael, 1985, Archives of internal medicine.

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis

G. Wells, S. Kelly, B. Skidmore, 2020, PloS one.

Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies

L. Huebsch, J. Maroun, D. Stewart, 2004, Journal of Neuro-Oncology.

Topotecan in the first-line treatment of small cell lung cancer.

D. Stewart, 2004, The oncologist.

Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis)

M. Keating, D. Stewart, 1980, Cancer.

Natural history of central nervous system acute leukemia in adults

E. Freireich, M. Keating, G. Bodey, 1981, Cancer.

Sorafenib‐induced premalignant and malignant skin lesions

Philip R. Cohen, D. Stewart, V. Williams, 2011, International journal of dermatology.

Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer

B. Győrffy, A. Pandiella, P. Pérez-Segura, 2021, Frontiers in Oncology.

A Randomized Phase II Study of Cisplatin Alone Versus Cisplatin Plus Disulfiram

J. Maroun, D. Stewart, S. Verma, 1990, American journal of clinical oncology.

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

U. Gatzemeier, F. Fossella, M. Reck, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer

M. Spitz, J. Gu, Xifeng Wu, 2008, British Journal of Cancer.

Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors.

W. Walsh, J. Maroun, D. Stewart, 1990, The Journal of urology.

A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors

D. Stewart, 2005, Journal of Neuro-Oncology.

Remission from central nervous system involvement in adults with acute leukemia effect of intensive therapy and prognostic factors

Terry L. Smith, E. Freireich, M. Keating, 1985, Cancer.

Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid.

R. Benjamin, W. Plunkett, M. Burgess, 1979, Cancer research.

Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

R. M. Green, J. Maroun, D. Stewart, 2004, Investigational New Drugs.

Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.

M. Valdivieso, D. Stewart, E. C. Moore, 1980, Cancer research.

Systemic therapy for lung cancer brain metastases: a rationale for clinical trials.

Y. Oh, D. Stewart, 2008, Oncology.

Penetration of teniposide (VM-26) into human intracerebral tumors

D. Stewart, H. Hugenholtz, H. Hopkins, 1984, Journal of Neuro-Oncology.

Human central nervous system and plasma pharmacology of mitoxantrone

R. M. Green, D. Stewart, H. Hugenholtz, 2004, Journal of Neuro-Oncology.

Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies.

L. Eapen, G. Raaphorst, P. Wong, 1994, International journal of radiation oncology, biology, physics.

Preliminary Experience With Menogaril in the Treatment of Recurrent Glioblastomas

D. Stewart, 1987 .

Human central nervous system pharmacology of tiazofurin

R. M. Green, D. Stewart, H. Hugenholtz, 1986 .

Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma

L. Eapen, J. Maroun, D. Stewart, 1986 .

Adriamycin in the treatment of malignant meningiomas

J. Maroun, D. Stewart, R. Bélanger, 1986 .

Phase II study of novantrone (mitroxantrone hydrochloride) in adults with grade III-IV astrocytomas

J. Maroun, D. Stewart, H. Hugenholtz, 1986 .

High-pressure liquid chromatographic analysis of 3-deazauridine-5'-triphosphate in human cancer cells.

W. Plunkett, D. Stewart, J. Benvenuto, 1979, Cancer treatment reports.

Pharmacokinetics and disposition of 3-deazauridine in humans.

R. Benjamin, D. Farquhar, D. Stewart, 1979, Cancer research.

Penetration of Baker's antifolate (NSC 139105) & 3-deazauridine (NSC 126849) into the central nervous system of man

R. Benjamin, D. Stewart, M. Leavens, 1979 .

Phase I study of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

J. Maroun, D. Stewart, 2004, Investigational New Drugs.

Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

D. Stewart, 2010, Critical reviews in oncology/hematology.

Pharmacokinetics and Dispositionof 3-Deazauridine in Humans 1

D. Farquhar, D. Stewart, J. Benvenuto, 2006 .

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

M. Spitz, J. Gu, Xifeng Wu, 2011, Lung cancer.

Redefining cancer: a new paradigm for better and faster treatment innovation.

G. Batist, D. Stewart, 2014, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer

M. Spitz, Hushan Yang, Xifeng Wu, 2007, Clinical Cancer Research.

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

R. Kurzrock, F. Janku, D. Stewart, 2010, Nature Reviews Clinical Oncology.

Review Wnt Signaling Pathway in Non–small Cell Lung Cancer Overview of the Wnt Canonical (β-catenin) and Noncanonical Signaling Pathways

D. Stewart, David J Stewart, David J Stewart, 2022 .

Potential insights from population kinetic assessment of progression-free survival curves.

D. Bossé, A. Ocaña, A. Robinson, 2020, Critical reviews in oncology/hematology.

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.

E. Eisenhauer, R. Donehower, A. Macleod, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.

D. Maziak, F. Shamji, P. Macleod, 2004, Lung cancer.

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.

K. Pritchard, M. Trudeau, D. Stewart, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.

P. O'dwyer, R. Bukowski, G. Goss, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib

I. Wistuba, Ximing Tang, H. Erickson, 2012, Science Translational Medicine.

Banibrata Sen Dasatinib Mutations in Lung Cancer Confer Sensitivity to BRAF Kinase-Impaired

Ignacio Wistuba, Faye M. Johnson, David J. Stewart, 2012 .

Mechanisms of resistance to cisplatin and carboplatin.

D. Stewart, David J Stewart, 2007, Critical reviews in oncology/hematology.

miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.

T. Perkins, J. Bar, G. Goss, 2015, Clinical lung cancer.

Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?

C. Chiu, Kuo‐Ting Chang, Yuh-Min Chen, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

miR Pro fi ling Identi fi es Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non e Small-Cell Lung Carcinoma

T. Perkins, J. Bar, G. Goss, 2022 .

Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial

Edward S. Kim, Jing Wang, J. Minna, 2013 .

Intra-arterial cisplatin treatment of unresectable or medically inoperable invasive carcinoma of the bladder.

J. Maroun, D. Stewart, P. Rasuli, 1984, Journal of Urology.

Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy

Joe Y. Chang, M. Spitz, Hushan Yang, 2008, Pharmacogenetics and genomics.

Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

M. Spitz, S. Lippman, J. Gu, 2011, Carcinogenesis.

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors

I. Wistuba, J. Issa, J. Jelinek, 2014, Clinical Epigenetics.

Lung Cancer Resistance to Chemotherapy

D. Stewart, 2010 .

Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms

Constance M. Johnson, B. Bekele, Adriana López, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

I. Wistuba, J. Issa, J. Jelinek, 2009, Clinical Cancer Research.

Intra-arterial cisplatin for bladder cancer.

L. Eapen, D. Stewart, W. Evans, 1987, The Journal of urology.

Novel modes of chemotherapy administration.

D. Stewart, 1984, Progress in experimental tumor research.

Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).

R. Caprioli, S. Wallace, R. Benjamin, 1983, Cancer research.

Phase I-II trial of intracarotid (IC) cis-diamminedichloroplatinum (DDP) in patients with intracerebral tumors (ICT)

S. Wallace, L. Feun, D. Stewart, 1982 .

Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

R. Caprioli, R. Benjamin, L. Feun, 1982, Cancer research.

Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

A. Peled, J. Burger, O. Wald, 2011, Expert review of anticancer therapy.

14 – Clinical Management of Lung Cancer

D. Stewart, 2010 .

Fool’s gold, lost treasures, and the randomized clinical trial

R. Kurzrock, D. Stewart, 2013, BMC Cancer.

Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer

G. Gladish, R. Munden, R. Herbst, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.

S. Dahrouge, E. Tomiak, D. Stewart, 2007, Cancer treatment reviews.

Cancer research in the United States: Dying by a thousand paper cuts

L. Zwelling, H. Kantarjian, D. Stewart, 2013, Cancer.

Equipoise lost: ethics, costs, and the regulation of cancer clinical research.

R. Kurzrock, D. Stewart, S. Whitney, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expression.

D. Jonker, G. Goss, J. Maroun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

S. Lippman, I. Wistuba, J. Erasmus, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment

W. William, D. Stewart, 2010 .

Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer.

J. Roth, I. Wistuba, C. Behrens, 2011, Lung cancer.

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria

L. Krug, C. Langer, G. Blumenthal, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer: the road to Amiens.

R. Kurzrock, D. Stewart, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The need for speed in advanced non‐small cell lung cancer: A population kinetics assessment

H. Sekhon, C. Dennie, M. Gomes, 2021, Cancer medicine.

Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer.

C. Earle, S. Dahrouge, S. Gertler, 1997, Lung cancer.

Etoposide With or Without Mannitol for the Treatment of Recurrent or Primarily Unresponsive Brain Tumors: A Children's Cancer Group Study, CCG-9881

J. Finlay, Jeffrey C. Allen, R. Packer, 2004, Journal of Neuro-Oncology.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

R. Govindan, G. Fasola, P. Postmus, 2018, Cancer.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

S. Banerji, M. Tsao, G. Nicholas, 2019, Current oncology.

Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases

Dima Suki, Raymond Sawaya, R. Komaki, 2009, Cancer.

Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans

J. Roth, I. Wistuba, J. Lee, 2012, PloS one.

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Jian Gu, Joe Y. Chang, Yuanqing Ye, 2011, Journal of the National Cancer Institute.

Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.

John J. Shin, P. Wheatley‐Price, D. Stewart, 2019, The oncologist.

Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.

F. Fossella, C. Lathia, M. Reck, 2011, Cancer biomarkers : section A of Disease markers.

Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.

J. Maroun, D. Stewart, L. Tétreault, 1985, Cancer treatment reports.

Determinants of the Cancer Drug Funding Process in Canada

John J. Shin, P. Wheatley‐Price, D. Stewart, 2019, Current oncology.

Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck

J. Maroun, D. Stewart, C. Cripps, 2004, Cancer Chemotherapy and Pharmacology.

Abstract 1774: Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy

D. Bossé, A. Robinson, D. Stewart, 2017 .

Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer.

M. Spitz, S. Lippman, J. Gu, 2011, Carcinogenesis.

Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.

E. Plimack, J. Issa, D. Stewart, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples

I. Wistuba, J. Issa, J. Jelinek, 2014, Clinical Epigenetics.

Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment

K. Thavorn, D. Stewart, A. Awan, 2019, Cancer medicine.

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

K. Hess, I. Wistuba, J. Issa, 2015, Clinical Epigenetics.

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

D. Berry, R. Kurzrock, F. Janku, 2012, Clinical Cancer Research.

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009

D. Berry, R. Kurzrock, F. Janku, 2012 .

Phase I study of intracarotid PCNU

J. Maroun, D. Stewart, H. Hugenholtz, 2004, Journal of Neuro-Oncology.

Phase I study of intraarterial mitomycin-c for recurrent intracerebral tumors

J. Maroun, D. Stewart, H. Hugenholtz, 1986 .

Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors

D. Stewart, H. Hugenholtz, Z. Grahovac, 1993, Journal of Neuro-Oncology.

Intracarotid Chemotherapy with a Combination of 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-Diaminedichloroplatinum (Cisplatin), and 4'-O-Demethyl-1-O-(4,6-O-2-thenylidene-β-D-glucopyranosyl)epipodophyllotoxin (VM-26) in the Treatment of Primary and Metastatic Brain Tumors

J. Maroun, D. Stewart, H. Hugenholtz, 1984 .

Phase II Study of High‐Dose Mitoxantrone in the Treatment of Recurrent Squamous Cell Carcinoma of the Head and Neck

J. Maroun, D. Stewart, C. Cripps, 1987, American journal of clinical oncology.

Mitomycin-C plus metronidazole in advanced carcinoma of the breast

J. Maroun, D. Stewart, R. Heringer, 2005, Breast Cancer Research and Treatment.

Treatment of malignant gliomas in adults with BCNU plus metronidazole

J. Maroun, D. Stewart, H. Hugenholtz, 2004, Journal of Neuro-Oncology.

Phase I study of idarubicin administered orally on a daily × 3 schedule

J. Maroun, D. Stewart, Sunil Gupta, 1990, Investigational New Drugs.

Bioavailability and pharmacology of oral idarubicin

S. Gupta, R. M. Green, J. Maroun, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study

J. Maroun, D. Stewart, L. Morgan, 2007, Investigational New Drugs.

Tumor penetration of AMSA in man.

R. Benjamin, N. Savaraj, L. Feun, 1983, Cancer investigation.

A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults

S. Dahrouge, D. Stewart, K. Soltys, 2005, Journal of Neuro-Oncology.

Prognostic factors in hairy cell leukemia. (Leukemic reticuloendotheliosis)

E. Hersh, J. Quesada, E. Freireich, 1984, Cancer.

Equipoise abandoned? Randomization and clinical trials.

R. Kurzrock, D. Stewart, David J. Stewart, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors

R. Benjamin, N. Savaraj, L. Feun, 2004, Journal of Neuro-Oncology.

Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986)

R. Benjamin, N. Savaraj, L. Feun, 1983, Journal of Neuro-Oncology.

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer

Diane D. Liu, W. Hong, J. Roth, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer

L. Seymour, G. Batist, S. Gertler, 2005, Lung.

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin

L. Seymour, W. Walsh, C. Lathia, 2004, Investigational New Drugs.

The presence in human tumours of a Mr 11,700 calcium-binding protein similar to rodent oncomodulin.

J. Whitfield, D. Stewart, J. Macmanus, 1984, Cancer letters.

Phase II study of tiazofurin in gliomas in adults

J. Cairncross, E. Eisenhauer, D. Macdonald, 1993, Journal of Neuro-Oncology.

Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.

S. Lippman, J. Gu, Xifeng Wu, 2012, Carcinogenesis.

Cancer research in the United States: A critical review of current status and proposal for alternative models

Razelle Kurzrock, David P Steensma, R. Kurzrock, 2018, Cancer.

Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer

Joe Y. Chang, M. Spitz, J. Minna, 2010, PloS one.

A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.

D. Jonker, D. Bossé, G. Goss, 2020, Critical reviews in oncology/hematology.

Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.

R. Kurzrock, A. Tsimberidou, F. Braiteh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

R. Kurzrock, G. Batist, H. Kantarjian, 2015, Clinical Cancer Research.

High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation

Milind B. Suraokar, J. Lee, W. Franklin, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

I. Wistuba, J. Lee, S. Swisher, 2013, Clinical Cancer Research.

Review wnt Signaling Pathway in Non – Small Cell Lung Cancer

D. Stewart, 2014 .

Can EGFR mutation status evolve with chemotherapy?

A. Khorana, Eric S Kim, D. Stewart, 2012, Chinese clinical oncology.

Epidermal growth factor receptor (EGFR) inhibition by oral tyrosine kinase inhibitors (TKIs) and platinum- based chemotherapy are important treatment strategies for advanced non-small-cell lung cancer (NSCLC)

A. Khorana, Eric S Kim, D. Stewart, 2013 .

The importance of greater speed in drug development for advanced malignancies

Razelle Kurzrock, Mark Clemons, Gerald Batist, 2018, Cancer medicine.

Chapter 6 – Lung Cancer

S. Swisher, R. Komaki, J. Erasmus, 2012 .

Imaging , Diagnosis , Prognosis EZH 2 Protein Expression Associates with the Early Pathogenesis , Tumor Progression , and Prognosis of Non – Small Cell Lung Carcinoma

I. Wistuba, J. Lee, S. Swisher, 2013 .

PROSPECT (Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification)

W. Hong, D. Stewart, W. Hong, 2008 .

Click chemistry, 3D-printing, and omics: the future of drug development

Razelle Kurzrock, R. Kurzrock, D. Stewart, 2015, Oncotarget.

Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer

J. Cox, D. Stewart, 2010 .

High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases.

S. Gertler, F. Shamji, A. Tomiak, 1994, Lung cancer.

5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.

D. Stewart, S. Aitken, S. Huan, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Active chemotherapy for metastatic stromal cell tumor of the testis.

D. Stewart, K. T. Mai, D. Stewart, 1993, Urology.

Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

R. Herbst, L. Paz-Ares, M. Sebastian, 2007 .

Pharmacology of pentamethylmelamine in humans.

R. Benjamin, D. Stewart, J. Benvenuto, 1981, Cancer research.

RAPID framework for improved access to precision oncology for lethal disease: Results from a modified multi-round delphi study

A. Mills, D. Stewart, K. Bright, 2023, Frontiers in Health Services.

Treatment Access, Health Economics, and the Wave of a Magic Wand

G. Batist, D. Stewart, John-Peter Bradford, 2022, Current oncology.

Imaging of the patient with non-small cell lung cancer.

R. Munden, C. Stevens, S. Swisher, 2005, Radiology.

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

E. Eisenhauer, V. Bramwell, A. Paterson, 1988, Investigational New Drugs.

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

J. Erasmus, D. Stewart, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High-performance liquid chromatographic analysis of pentamethylmelamine and its metabolites in biological fluids.

R. Benjamin, D. Stewart, J. Benvenuto, 1981, Journal of chromatography.

Addition of Pentoxifylline plus Nifedipine to Chemotherapy in Patients with Cisplatin‐Resistant Cancers of the Lung and Other Sites

D. Stewart, D. Logan, W. Evans, 1994, American journal of clinical oncology.

Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary and metastatic brain tumors.

J. Maroun, D. Stewart, H. Hugenholtz, 1984, Neurosurgery.

Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies

J. Gutterman, N. Savaraj, L. Feun, 2004, Journal of Neuro-Oncology.

Prolonged Disease‐Free Survival Following Surgical Debulking and High‐Dose Cisplatin/Doxorubicin in a Patient with Bulky Metastases from Giant Cell Tumor of Bone Refractory to “Standard” Chemotherapy

D. Stewart, R. Bélanger, and Robert S. Benjamin, 1995, American journal of clinical oncology.

A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC).

I. Wistuba, J. Lee, J. Fujimoto, 2013 .

Abstract 787: Differences in protein expression patterns in lung adenocarcinomas arising in never versus ever smokers

Menghong Sun, J. Minna, Xiaoling Li, 2010 .

Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.

R. M. Green, M. Redmond, D. Stewart, 1993, Anticancer research.

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin

B. Schwartz, C. Lathia, D. Stewart, 2005, Investigational New Drugs.

M. Spitz, J. Minna, S. Lippman, 2014, Clinical pharmacology and therapeutics.

Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans.

R. Benjamin, B. Yap, D. Stewart, 1981, Cancer research.

Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.

T. Newman, D. Stewart, W. Evans, 1997, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours.

S. Bates, L. Seymour, W. Walsh, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC).

S. Lippman, R. Lotan, I. Wistuba, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraarterial Mitomycin‐C for Recurrent Brain Metastases

C. Danjoux, J. Maroun, D. Stewart, 1987, American Journal of Clinical Oncology.

Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies

S. Lippman, R. Herbst, Y. Oh, 2008 .

Translating Clinical Trials into Meaningful Outcomes

P. LoRusso, Walter Wolf, S. Boerner, 2010, Clinical Cancer Research.

Disposition of methylglyoxal bis(guanylhydrazone) (MGBG, NSC-32946) in man

D. Stewart, M. Rosenblum, M. Luna, 2004, Cancer Chemotherapy and Pharmacology.

Doxorubicin Plus Metronidazole in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

D. Stewart, M. Cripps, P. Odell, 1993, American Journal of Clinical Oncology.

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.

T. Cascino, J. Buckner, D. Macdonald, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

J. Hirsh, M. Gent, V. Bramwell, 1994, The Lancet.

Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, F. Shepherd, M. Crump, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of paclitaxel (TaxolQ) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer*

E. Eisenhauer, F. Shepherd, M. Crump, 1996 .

Concurrent chemotherapy with hyperfractionated accelerated thoracic irradiation in stage III non-small cell lung cancer.

S. Dahrouge, O. Agboola, G. Goss, 1999, Lung cancer.

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

I. Tannock, K. Bélanger, L. Seymour, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.

J. Maroun, D. Stewart, H. Hugenholtz, 1987, Seminars in oncology.

Cisplatin, arabinofuranosyl cytosine, and caffeine before radiation for glioblastomas

J. Maroun, D. Stewart, H. Hugenholtz, 1986 .

Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered cis-dichlorodiammineplatinum(II)

R. Caprioli, R. Benjamin, D. Stewart, 2004, Cancer Chemotherapy and Pharmacology.

Relationship between urine beta-2-microglobulin and platinum levels during cisplatin treatment.

A. Nanji, D. Stewart, N. Mikhael, 1988, Clinical Biochemistry.

A Pilot Study of Low Dose Hydroxyurea as a Novel Resistance Modulator in Metastatic Renal Cell Cancer

D. Stewart, S. Huan, R. Segal, 2000, Journal of chemotherapy.

Human autopsy-tissue distribution of menogaril and its metabolites

R. M. Green, D. Stewart, R. Earhart, 2004, Cancer Chemotherapy and Pharmacology.

Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.

S. Lippman, J. Gu, Xifeng Wu, 2012, Carcinogenesis.

Management of egfr tki-induced dermatologic adverse events.

N. Leighl, K. Papp, B. Melosky, 2015, Current oncology.

Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer

M. Spitz, Hushan Yang, Xifeng Wu, 2007, Clinical Cancer Research.

Reply to A. Ocana et al

R. Kurzrock, D. Stewart, 2010 .

Wnt signaling pathway in non-small cell lung cancer.

D. Stewart, 2014, Journal of the National Cancer Institute.

Decitabine effect on human tumor expression of various transporters.

I. Wistuba, J. Issa, J. Jelinek, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.

T. Perkins, J. Bar, G. Goss, 2015, Clinical lung cancer.

Phase I Study of Acivicin and Cisplatin in Non‐Small‐Cell Lung Cancer: A National Cancer Institute of Canada Study

E. Eisenhauer, J. Maroun, D. Stewart, 1990, American journal of clinical oncology.

PET/CT-guided Involved-field Intensity Modulated Radiation Therapy for Limited-stage Small Cell Lung Cancer

S. Lippman, S. Shirvani, R. Komaki, 2010 .

5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.

R. Wierzbicki, J. Maroun, J. Rusthoven, 1990, Cancer investigation.

DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

M. Spitz, C. Amos, Q. Dong, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intracarotid infusion of PCNU (NSC: 95466): Preclinical toxicological study in dogs

L. Goumnerova, D. Stewart, V. Montpetit, 2004, Journal of Neuro-Oncology.

Nausea and Vomiting in Cancer Patients

D. Stewart, 2017 .

Equipoise lost: ethics, costs, and the regulation of cancer clinical research.

R. Kurzrock, D. Stewart, S. Whitney, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.

D. Stewart, P. Wheatley-Price, 2021, JAMA oncology.

Population kinetics of progression free survival (PFS).

M. Clemons, D. Bossé, A. Ocaña, 2019, Journal of Clinical Oncology.